The drugs reportedly under consideration for coverage include Novo Nordisk's Wegovy and Ozempic, and Eli Lilly's Zepbound and ...

A move to cover expensive weight-loss drugs for Americans on Medicare and Medicaid may be in the works, but any such program ...

The number of U.S. adults that are aware of GLP-1 drugs used for weight loss, such as Ozempic and Wegovy, has jumped significantly in the last few years, a new survey shows. The YouGov poll, ...

Eli Lilly remains a top stock to buy and hold. Vertex Pharmaceuticals is moving quickly to expand its markets beyond cystic ...

According to the Washington Post, 13 states currently cover the drugs for Medicaid patients, while Medicare prohibits ...

Eli Lilly, Novo Nordisk Shares Rally As Trump Administration Reportedly Plans To Experiment Including Weight-loss Drugs Under ...

The U.S. Food and Drug Administration on Wednesday approved Eli Lilly & Co.’s LLY obesity drug Zepbound, which in clinical trials helped patients lose up to 48 pounds on average. The drug was ...

Craft beer is in decline. For the first time in nearly two decades in the U.S., more breweries closed in 2024 than opened, ...

Novo Nordisk has reported another significant criticality: the presence of unauthorized versions of its drugs on the US ...